A clinical trial to assess the safety and effectiveness of a new medication called MK-1942 in the treatment of mild and moderate Alzheimer’s Disease

Occurring Dates
Participant Duration
8 appointments at our Malvern clinic over 14 weeks. The length of the appointments will vary from 30 min to 3 hours.
State of study

MK-1942 is a molecule that promotes the release of a chemical in the brain called glutamate. Glutamate release in the brain has been linked to improved cognition. This trial will investigate whether MK-1942 can improve cognitive when compared to placebo in people with mild to moderate Alzheimer's disease.

This study has been approved by the Bellberry Human Research Ethics Committee (2022-07-763)

Participation details

We are seeking participants who meet the following criteria:

  • have early Alzheimer’s disease
  • be between 55 and 80 years old (inclusive).
  • have a study partner (a next of kin or someone you have a close relationship to), who is willing to take part in the study and share information about you
  • must be taking an approved Alzheimer's disease treatment (such as Aricept, Reminyl, Exelon, etc) and must be on a stable dose of that medication for at least 3 months.
  • live in Victoria and can attend a clinic in Malvern

If you are interested in participating or would like more information please contact A/Prof Stephen Macfarlane (details below)

Study Address
Level 1, 322 Glenferrie Road, Malvern VIC 3144
Full Name
A/Prof Stephen Macfarlane
HammondCare Aged Psychiatry Clinical Trials (Malvern)
Phone Number
09 9597 6518